…Day April Bowel Cancer Awareness Month IBS (irritable bowel syndrome) Awareness Month Parkinson’s Awareness Month 7 World Health Day 10 Parkinson’s Awareness Week 11 World Parkinson’s Day 13 World Sarcoidosis…
…there were no serious adverse events (SAEs). Parkinson’s disease program under way by NodThera Development of NT-0796 is now progressing in a pioneering, biomarker-rich phase Ib/IIa study in Parkinson’s disease….
…therapy for treating Parkinson’s disease, and intends to initiate a global non-interventional study for Parkinson’s patients in the second half of 2022. “Today’s announcement is a significant step forward in…
…pipeline aimed at multiple neurodegenerative diseases, the company is also developing immunotherapies for Parkinson’s and diagnostics for Alzheimer’s and progressive supranuclear palsy. Founded: 2012 Field: Cancer A decade after they…
…patients with Parkinson’s disease because they didn’t feel comfortable explaining the meaning of test results to patients (19.6 percent) and because they were worried about the implications of the patient’s…
…interactions. The company acknowledges that there is a need for a novel approach to target CNS diseases such as Alzheimer’s and Parkinson’s diseases as they are caused by an accumulation…
…Parkinson’s disease or a dog with diabetes as you would any product on the internet. But the ethical issues surrounding animal testing beg the question: are there equally relevant models…
…disease, ALS, Parkinson’s disease and Huntington’s disease. Most of these conditions are difficult to treat; for example, many drugs have failed to tackle Alzheimer’s disease in clinical trials over the…
…is dedicated to investing in early-stage ventures that develop disease-modifying therapeutics for all types of dementia, including Alzheimer’s and Parkinson’s. Yesterday, the DDF completed a $350 (€300M) fundraising that far…
…Moreover, AC Immune’s monoclonal antibody crenezumab, which also targets misfolded Abeta, is being examined in a prevention trial in Colombia. The biotech is also focused on treating Parkinson’s disease, for…
…managed to get its Parkinson’s drug approved earlier this year. In doing this, it became one of the first biotechs in the EU with an approved CNS drug. Xadago tackles…
…and Parkinson’s disease. “We are extremely excited about this opportunity, which is such a large funding round in a European company,” Marco Boorsma, General Partner at Forbion, the lead investor…